🔗 Share this article

Given that America proceeds with historic changes to its immunization guidelines, a particular individual has surfaced somewhat surprisingly: Tracy Beth Høeg, a Danish American sports physician and public health researcher who rose to prominence by casting doubt on coronavirus vaccines during the global health crisis and has zeroed in on alleged fatalities following COVID-19 vaccination in her brief position at the US Food and Drug Administration (FDA).

Scheduled Shifts to Pediatric Vaccine Program

Health officials had intended to announce major changes to the childhood vaccination calendar in December, bringing the US with the Danish immunization schedule, according to reports – a major change that would place the US out of alignment with much of the world with little proof for benefit. The planned update has been delayed until the next year.

In place of Vinay Prasad, Dr. Høeg is scheduled to present at the event. She was newly appointed interim head of the FDA’s CDER, the fifth appointee to lead the division this calendar year.

A New Direction at the Regulatory Body

The acting appointment could signify a tighter collaboration between the drug and vaccine divisions as Høeg and Dr. Prasad strengthen their influence at the FDA – and it signals a increased emphasis upon dismantling long-standing immunizations at the FDA.

The new acting director has frequently advocated for ending certain pediatric immunization guidelines in the US to become more similar to Denmark's approach, a society with comprehensive healthcare and a number of inhabitants approximately the population of the state of Wisconsin.

So far comments, she has kept her attention on vaccines – traditionally the responsibility of Prasad, head of the FDA’s vaccine center – instead of pharmaceutical oversight.

Doubts Over Qualifications

The appointee has no obvious experience in pharmaceutical research, regulation or management, which has been typical for past directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the FDA chief and CBER since earlier this year.

“She doesn’t seem to have the necessary background” for leading the pharmaceutical oversight division, said a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She has no expertise in managing a sizeable institution. She is not an expert in drug approvals.”

Past directors of CBER would “understand laws and regulations and the research of medication creation”, commented Dr. Janet Woodcock. “Clearly, she has not acquired the type of experience that former directors who ran CBER have had.”

The drug center has an vast portfolio at the agency, she pointed out.

“Many people just zeroes in on the new drug program, but the off-patent medication office approves thousands of generic medications. There is also a biologic copycat branch, non-prescription drug unit and more, and all of those have to be managed,” she noted. “The thing you neglect, that is precisely what that I always told people is going to bite you.”

Furthermore, a substantial leadership component to the position, which manages in excess of 5,000 personnel. “It’s a massive administrative position, if you do it right,” the former official said.

Official Statement and Contentious Policies

When asked about concerns about Dr. Høeg's qualifications and whether this assignment represents greater collaboration among FDA leaders on vaccines, a press secretary responded that the “concerns are based on flawed presumptions”.

“This background is consistent with the functions of her role,” the spokesperson stated, noting the period Dr. Høeg spent advising the agency head on “medication safety and regulatory science, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg inherits the commissioner’s new fast-track approval initiative, a disputed expedited drug-approval program that allegedly troubled her preceding directors. “By what process are these drugs being selected for this voucher program? Who is making the decisions?” Howard asked. “There is a lot of secrecy going on at the FDA right now.”

Broadly speaking, he said, “the FDA appears to be shifting towards more relaxed regulations of all drugs, except for immunizations.”

Documented History on Vaccines

Regarding vaccines, Dr. Høeg has a more established, if troubling, history, some experts have noted. She authored a analysis using non-validated public submissions to assess the frequency of myocarditis following COVID-19 vaccination. She advised the state of Florida surgeon general Joseph Ladapo, who reportedly have altered data to indicate COVID-19 vaccines are more dangerous than they are.

Included in her “wish list” for the incoming government included altering regulations for novel immunizations and halting “unnecessary” immunizations, she said post-election on a audio program. At the agency, Høeg has according to sources proposed preventing teenage boys from receiving Covid vaccines.

“She’s an all-around ideologue who begins with her conclusions and works backwards to fit the data in a extremely deceptive, fraudulent way,” Howard stated.

Consolidating Power and a “Revenge Tour”

Dr. Høeg aligned with fellow contrarians, {like|